Company: HCWB
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0000950170-25-046724
Chunk: 82

Company: HCW Biologics Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 8
Chunk 82
---
,236,578

    LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

    Liabilities

    Current liabilities:

    Accounts payable
     
    $
    6,167,223

    $
    22,332,261

    Accrued liabilities and other current liabilities

    2,580,402

    981,940

    Short-term debt, net

    —

    6,314,684

    Total current liabilities

    8,747,625

    29,628,885

    Debt, net

    6,304,318

    7,377,865

    Total liabilities

    15,051,943

    37,006,750

    Commitments and contingencies (Note 17)

    Stockholders’ equity (deficit):

    Common stock:

    Common, $0.0001 par value; 250,000,000 shares authorized   and 36,025,104 shares issued at December 31, 2023; 250,000,000 shares    authorized and 44,541,295 shares issued at December 31, 2024

    3,603

    4,454

    Additional paid-in capital

    83,990,437

    93,781,511

    Accumulated deficit

    (70,532,323
    )

    (100,556,137
    )

    Total stockholders’ equity (deficit)

    13,461,717

    (6,770,172
    )

    Total liabilities and stockholders’ equity (deficit)
     
    $
    28,513,660

    $
    30,236,578

The accompanying notes are an integral part of these financial statements. 

99

HCW Biologics Inc. 

Statements of Operations 

    Years EndedDecember 31,

    2023

    2024

    Revenues:

    Revenues
     
    $
    2,841,794

    $
    2,566,792

    Cost of revenues

    (2,281,434
    )

    (1,607,389
    )

    Net revenues

    560,360

    959,403

    Operating expenses:

    Research and development

    7,676,316